- Home
- NCEL vs ATHA Comparison
NCEL vs ATHA Comparison
Compare NCEL & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCEL | ATHA |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 18.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NCEL | ATHA |
|---|---|---|
| Price | $3.75 | $4.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 147.3K | 26.2K |
| Earning Date | 12-01-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $2.20 |
| 52 Week High | $7.64 | $6.79 |
Technical Indicators
Market Signals| Indicator | NCEL | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.16 |
| Support Level | N/A | $4.31 |
| Resistance Level | N/A | $4.81 |
| Average True Range (ATR) | 0.00 | 0.36 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 47.12 |
Price Performance
Historical ComparisonAbout ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.